Category: Featured Content
-
Cybin (CYBN.NE) Closes Overnight Public Offering, Fortifies Cash Balance
Cybin (CYBN.NE) announced today that it has closed its previously announced overnight marketed offering including the exercise in full of the over-allotment option granted to the Underwriters. “Investor demand for this financing was very strong and we are thankful for the outstanding work of our banking syndicate partners and advisors and we welcome all new…
-
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
-
Buy Robin Hood (HOOD.Q)? Why don’t I just burn my money instead, at least I’ll get the warmth..
Technology has never been able to bring us an accurate means of assessing someone’s intelligence. The IQ test is a loose guide at best, career status can be boosted based on where you got your start in life and how much Great Uncle Cornelius left you, and number of social media followers only generally provides…
-
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
Xphyto (XPHY.C) partner/acquisition target achieves major milestone with Covid-19 biosensor candidates
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection. Xphyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. 3a-diagnostics is currently a commercial partner of…
-
Diagnos (ADK.V) Announces Pilot with Opticalia in Spain
Diagnos (ADK.V), a leader in early detection announced today that it has signed a pilot in Spain with three franchisees from Opticalia Group. “The campaign begins with the request for a previous appointment through the web or at the optician itself, where patients will register in order of arrival and a free retinography will be…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
Skyharbour’s (SYH.V) partner zeroes in on uranium targets at Hook Lake Project, Athabasca Basin
We began our coverage of Skyharbour Resources (SYH.V) back on June 9th in a piece titled Skyharbour Resources (SYH.V) an Athabasca Basin Uranium gem in the midst of an aggressive drill campaign. This cash-rich Athabasca Basin land baron has a number of highly prospective irons in the fire—a strapping project pipeline—in a region that boasts the…
-
Globex Mining (GMX.T) – a new acquisition, recent revenue generating headlines, notes from a chat with the CEO
In sifting through the rubble of the junior exploration arena of late, one need not spoor too far n wide to spot good value. Even the highest quality entities, those boasting compelling fundamentals—robust project pipelines, solid management, healthy balance sheets—are being tossed with little regard for their underlying intrinsic value. This current selling pressure in…